RTP Mobile Logo
Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Multiple Myeloma (Webinar Audio Proceedings)
Released February 2021

Proceedings from part 1 of a 4-part webinar series during the 62nd ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca, Ola Landgren, Nikhil C Munshi, Robert Z Orlowski and Edward A Stadtmauer. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

    LEARNING OBJECTIVES

    • Design and implement a plan of care for patients with newly diagnosed or relapsed/refractory multiple myeloma (MM), considering the applicability of existing and emerging clinical trial data.
    • Customize the use of induction, consolidation and maintenance therapeutic approaches for MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
    • Appreciate available clinical trial data documenting the efficacy of monoclonal antibody therapy directed at CD38 as a component of induction therapy, and effectively identify whether and how this strategy should be integrated into the clinical care of patients eligible or ineligible for stem cell transplant.
    • Recognize published research data validating the use of minimal residual disease (MRD) status as a mechanism to assess response to active therapy as well as identify the presence of disease recurrence, and use this information to determine the potential role of MRD testing in the protocol and off-protocol management of MM.
    • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
    • Develop an understanding of the mechanism of action and available data with recently FDA-approved novel therapies to facilitate their integration into current MM management algorithms.
    • Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates designed to target the B-cell maturation antigen, and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches as part of a clinical trial.
    • Assess ongoing clinical trials evaluating novel investigational approaches for MM, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Director for Innovation and Transformational Relationships
    Interim Executive Director of the Mayo Clinic Comprehensive Cancer Center
    Chair, Department of Internal Medicine
    Distinguished Mayo Investigator
    Mayo Clinic in Arizona
    Phoenix, Arizona

    Advisory Committee: Adaptive Biotechnologies Corporation, ONCOtracker Inc; Consulting Agreements: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Merck, Novartis, ONCOtracker Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology.

    Ola Landgren, MD, PhD
    Professor of Medicine
    Leader, Experimental Therapeutics Program
    Leader, Myeloma Program
    Sylvester Comprehensive Cancer Center
    University of Miami
    Miami, Florida

    Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc; Contracted Research: Amgen Inc, Janssen Biotech Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc, Merck, Takeda Oncology, Theradex Oncology.

    Nikhil C Munshi, MD
    Kraft Family Chair
    Director of Basic and Correlative Science
    Jerome Lipper Multiple Myeloma Center
    Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, BeiGene, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep.

    Robert Z Orlowski, MD, PhD
    Florence Maude Thomas Cancer Research Professor
    Department of Lymphoma and Myeloma
    Professor, Department of Experimental Therapeutics
    Director, Myeloma Section
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity).

    Edward A Stadtmauer, MD
    Section Chief, Hematologic Malignancies
    Roseman, Tarte, Harrow and Shaffer Families President’s Distinguished Professor
    University of Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania

    Consulting Agreements: Amgen Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Sanofi Genzyme, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme and Takeda Oncology.

    Release date: February 2021
    Expiration date: February 2022

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):